Charles Schwab’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-294,035
| Closed | -$1.42M | – | 3405 |
|
|
2020
Q1 | $1.42M | Buy |
294,035
+6,191
| +2% | +$40.1K | ﹤0.01% | 2400 |
|
|
2019
Q4 | $3.06M | Buy |
287,844
+12,563
| +5% | +$125K | ﹤0.01% | 2267 |
|
|
2019
Q3 | $2.87M | Buy |
275,281
+181,200
| +193% | +$2.37M | ﹤0.01% | 2248 |
|
|
2019
Q2 | $1.44M | Sell |
94,081
-596
| -0.6% | -$8.62K | ﹤0.01% | 2469 |
|
|
2019
Q1 | $1.22M | Buy |
94,677
+30,386
| +47% | +$344K | ﹤0.01% | 2496 |
|
|
2018
Q4 | $611K | Sell |
64,291
-264
| -0.4% | -$3.42K | ﹤0.01% | 2699 |
|
|
2018
Q3 | $1.07M | Buy |
64,555
+5,530
| +9% | +$88.7K | ﹤0.01% | 2607 |
|
|
2018
Q2 | $948K | Buy |
59,025
+4,700
| +9% | +$83.9K | ﹤0.01% | 2604 |
|
|
2018
Q1 | $832K | Buy |
54,325
+7,300
| +16% | +$114K | ﹤0.01% | 2577 |
|
|
2017
Q4 | $734K | Buy |
47,025
+6,825
| +17% | +$91.3K | ﹤0.01% | 2617 |
|
|
2017
Q3 | $447K | Hold |
40,200
| – | – | ﹤0.01% | 2748 |
|
|
2017
Q2 | $370K | Hold |
40,200
| – | – | ﹤0.01% | 2788 |
|
|
2017
Q1 | $344K | Buy |
40,200
+14,200
| +55% | +$129K | ﹤0.01% | 2780 |
|
|
2016
Q4 | $279K | Hold |
26,000
| – | – | ﹤0.01% | 2869 |
|
|
2016
Q3 | $282K | Hold |
26,000
| – | – | ﹤0.01% | 2810 |
|
|
2016
Q2 | $177K | Sell |
26,000
-2,000
| -7% | -$12.6K | ﹤0.01% | 2979 |
|
|
2016
Q1 | $131K | Hold |
28,000
| – | – | ﹤0.01% | 2959 |
|
|
2015
Q4 | $177K | Hold |
28,000
| – | – | ﹤0.01% | 2984 |
|
|
2015
Q3 | $248K | Hold |
28,000
| – | – | ﹤0.01% | 2897 |
|
|
2015
Q2 | $330K | Hold |
28,000
| – | – | ﹤0.01% | 2837 |
|
|
2015
Q1 | $406K | Buy |
28,000
+15,000
| +115% | +$230K | ﹤0.01% | 2713 |
|
|
2014
Q4 | $222K | Hold |
13,000
| – | – | ﹤0.01% | 2958 |
|
|
2014
Q3 | $162K | Hold |
13,000
| – | – | ﹤0.01% | 2997 |
|
|
2014
Q2 | $191K | Hold |
13,000
| – | – | ﹤0.01% | 3007 |
|
|
2014
Q1 | $265K | Hold |
13,000
| – | – | ﹤0.01% | 2854 |
|
|
2013
Q4 | $255K | Hold |
13,000
| – | – | ﹤0.01% | 2877 |
|
|
2013
Q3 | $613K | Hold |
13,000
| – | – | ﹤0.01% | 2466 |
|
|
2013
Q2 | $326K | Buy |
+13,000
| New | +$207K | ﹤0.01% | 2701 |
|
Charles Schwab's STML Position: Q2 2020 in Review
Charles Schwab sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 294,035 shares — an estimated $1.42M sold.
Charles Schwab first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $3.06M in Q4 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Charles Schwab reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Charles Schwab sold 294,035 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $1.42M.
- Charles Schwab first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
- Charles Schwab's Stemline Therapeutics, Inc. position peaked at $3.06M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Charles Schwab's 13F filing for Q2 2020, filed 14 Aug 2020.